Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio [Yahoo! Finance]
T. Rowe Price Group, Inc. (TROW)
Last t. rowe price group, inc. earnings: 4/28 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
trow.client.shareholder.com
Company Research
Source: Yahoo! Finance
Omega Funds; additional investors include Life Sciences at Goldman Sachs Alternatives, BVF Partners LP, funds managed by abrdn. Inc., accounts advised by T. Rowe Price Associates, Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures, and Alderline Group SPRING HOUSE, Pa. Feb. 4, 2026 /PRNewswire/ -- Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the closing of a $52 million Series A extension. New investor Andreessen Horowitz (a16z) joined Third Arc Bio's existing world-class investor syndicate to further validate the company's approach to deliver transformational therapies for patients. As part of the financing, a16z General Partner, Jorge Conde, joins Third Arc Bio's Board of Directors. Proceeds from the financing will enable Third Arc Bio to accelerate its I&I portfolio and deliver additional oncology programs into the cl
Show less
Read more
Impact Snapshot
Event Time:
TROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TROW alerts
High impacting T. Rowe Price Group, Inc. news events
Weekly update
A roundup of the hottest topics
TROW
News
- T. Rowe Price Group (NASDAQ:TROW) had its price target lowered by analysts at Deutsche Bank Aktiengesellschaft from $106.00 to $100.00. They now have a "hold" rating on the stock.MarketBeat
- T. Rowe Price Group (NASDAQ:TROW) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $95.00 to $90.00. They now have a "sell" rating on the stock.MarketBeat
- T. Rowe Price Group (NASDAQ:TROW) was upgraded by analysts at Argus to a "hold" rating.MarketBeat
- T. Rowe Price price target lowered to $123 from $128 at Morgan Stanley [Yahoo! Finance]Yahoo! Finance
- T. Rowe Price Group (NASDAQ:TROW) had its price target lowered by analysts at JPMorgan Chase & Co. from $108.00 to $106.00. They now have an "underweight" rating on the stock.MarketBeat
TROW
Earnings
- 2/4/26 - Miss
TROW
Sec Filings
- 2/6/26 - Form 4
- 2/4/26 - Form 8-K
- 1/27/26 - Form NPORT-P
- TROW's page on the SEC website